ini1 Antibody

What is INI1/SMARCB1 and why is it significant in diagnostic pathology?

INI1, also known as SMARCB1, is an integral component of the hSWI/SNF (SWItch/Sucrose Non-Fermentable) chromatin remodeling complex that facilitates DNA-dependent cellular processes including transcription, replication, and repair . The gene is frequently mutated or deleted in several aggressive pediatric cancers, including malignant rhabdoid tumors (MRTs), epithelioid sarcoma, and chordoma . INI1 antibody testing has become a standard part of diagnostic workup for these tumors because INI1 protein expression status provides crucial diagnostic and prognostic information. The antibody detects the presence or absence of the INI1 protein in formalin-fixed, paraffin-embedded (FFPE) tissue samples through immunohistochemistry (IHC) .

How should INI1 immunohistochemistry results be interpreted?

INI1 immunohistochemistry results are typically interpreted based on nuclear staining patterns:

• Retained expression: Diffuse positive nuclear staining in all tumor cells

• Totally lost/negative: Complete absence of nuclear positivity in all tumor cells

• Partially lost (mosaic pattern): Some cells retain nuclear expression while others show loss

The correct interpretation requires comparison with internal positive controls (non-neoplastic cells should show positive nuclear staining) and careful evaluation of the staining intensity and distribution. INI1 staining should be considered retained only when all tumor cells demonstrate nuclear expression . The mosaic pattern shows considerable intertumoral and intratumoral variability, ranging from <10% to >50% immunonegative nuclei .

What tissue processing methods are compatible with INI1 antibody testing?

INI1 antibody testing is optimized for:

• Formalin-fixed, paraffin-embedded (FFPE) tissue sections

• Manual qualitative immunohistochemistry testing platforms

• Automated IHC systems like the Ventana BenchMark XT Autostainer

Antigen retrieval methods that show good results include:

• Microwave-based retrieval

• Steam-based retrieval in a Borg Decloaker RTU (48 minutes)

• Heat-induced epitope retrieval (HIER) systems

The detection systems compatible with INI1 antibody include Leica Biosystems Refine Detection Kit with citrate antigen retrieval and Ventana "Ultra View Universal DAB Detection Kit" .

How do different mutations in SMARCB1 gene correlate with INI1 protein expression patterns?

The relationship between specific SMARCB1 genetic variants and INI1 protein expression is complex. Research has shown that different mutation types can lead to varying expression patterns:

Studies investigating the relationship between SMARCB1 genetic variants identified by next-generation sequencing (NGS) and INI1 protein expression have found that while most mutations lead to protein loss, the extent and pattern of loss can vary based on the specific genetic alteration . Additionally, some tumors may show discordance between genetic findings and protein expression, suggesting post-transcriptional or post-translational regulatory mechanisms.

What is the significance of mosaic INI1 expression patterns in schwannomas?

Mosaic INI1 expression patterns have significant diagnostic and etiological implications in schwannomas. Research has demonstrated striking differences in INI1 expression patterns between different types of schwannomas:

• 93% of tumors from familial schwannomatosis patients show mosaic INI1 expression

• 55% of tumors from sporadic schwannomatosis cases show mosaic expression

• 83% of NF2-associated tumors demonstrate mosaic expression

• Only 5% of solitary, sporadic schwannomas show mosaic expression

These findings confirm a role for INI1/SMARCB1 in multiple schwannoma syndromes and suggest that different pathways of tumorigenesis occur in solitary, sporadic tumors compared to syndrome-associated schwannomas. The mosaic pattern indicates that complete loss of INI1 function may not be necessary for tumor formation in these contexts, and partial loss may be sufficient to drive tumorigenesis in certain genetic backgrounds .

How does INI1 protein interact with HIV-1 integrase, and what are the implications?

INI1/SMARCB1 binds to HIV-1 integrase (IN) through its Rpt1 domain (amino acids 183-248) and plays a multifaceted role in HIV-1 replication. NMR structure determination and computational modeling have revealed that:

• The INI1-Rpt1/IN-CTD (C-terminal domain) interface residues overlap with those required for IN/RNA interaction

• INI1-Rpt1 and TAR RNA compete with each other for IN binding with similar IC₅₀ values

• Specific residues in the IN-CTD (including K264, R269, W235, and R228) are critical for both INI1 binding and TAR RNA binding

• INI1-Rpt1 domain structurally mimics TAR RNA, explaining the competitive binding

These interactions have significant implications for HIV-1 particle morphogenesis. INI1-interaction-defective IN mutant viruses are impaired for incorporation of INI1 into virions and show defects in particle formation. The binding of INI1 to IN can be disrupted by specific mutations:

• D225G and T214A mutants in INI1-Rpt1 significantly disrupt binding to IN

• D227G mutation in INI1-Rpt1 has less impact on binding

• W235E, R228A, and R269A/K273A mutations in IN disrupt INI1 binding

Understanding these interactions provides insights into novel strategies to inhibit HIV-1 replication by targeting the IN-INI1 interface.

What methodological approaches are most effective for studying INI1 loss in tumor samples?

Multiple complementary methodological approaches provide the most comprehensive assessment of INI1 status in tumor samples:

• Immunohistochemistry (IHC):

  • Primary method for detecting protein loss

  • Most commonly used antibody clones: BD Transduction Laboratories anti-INI1, ZR282 rabbit monoclonal

  • Optimal dilution ranges: 1:25 to 1:100 depending on detection system

  • Critical to include appropriate controls: AT/RT as negative control, medulloblastoma and normal cortex as positive controls

• Next-Generation Sequencing (NGS):

  • Detects underlying genomic alterations in SMARCB1

  • Can identify point mutations, deletions, and complex rearrangements

  • Important for identifying germline mutations in familial cases

• Fluorescence In Situ Hybridization (FISH):

  • Detects homozygous deletions of SMARCB1 locus

  • Useful when IHC results are ambiguous or discordant with clinical features

• Combined immunophenotyping and molecular analysis:

  • Correlation of mutation type with protein expression pattern

  • Integration with other markers such as PD-L1 and CD8 to assess potential immunotherapy relevance

How can INI1 expression analysis be integrated with immunotherapy biomarker assessment?

Recent research has explored the relationship between INI1 deficiency and potential responsiveness to immunotherapy. A methodological approach for integrating INI1 testing with immunotherapy biomarker assessment includes:

• Sequential staining with anti-INI1 antibody and immune markers (PD-L1, CD8, CD163)

• Assessment of INI1 status (retained, totally lost, or partially lost)

• Evaluation of PD-L1 expression in both tumor cells and tumor-infiltrating lymphocytes (TILs)

• Quantification of CD8+ T-cell infiltration and CD163+ macrophages

• Correlation of these parameters with genomic alterations in SMARCB1

The extent of PD-L1 staining should be recorded as a percentage in both tumor cells and TILs, with a threshold of ≥1% PD-L1 staining considered "positive" . Early reports suggest a potential role for immune checkpoint inhibition in patients with INI1-deficient tumors, making this integrated assessment valuable for treatment planning.

What are the optimal antibody concentrations and staining protocols for INI1 immunohistochemistry?

Based on published protocols, optimal conditions for INI1 immunohistochemistry include:

When using the Leica Bond system, the Leica Biosystems Refine Detection Kit with citrate antigen retrieval is recommended. For Ventana systems, the "Ultra View Universal DAB Detection Kit" with HIER provides optimal results .

What are the potential pitfalls in INI1 immunohistochemical analysis?

Researchers should be aware of several potential pitfalls when performing and interpreting INI1 immunohistochemistry:

• Fixation artifacts: Inadequate fixation can lead to false-negative or patchy staining patterns

• Interpretation challenges:

  • The mosaic pattern can be subtle and requires careful examination

  • The threshold for defining "loss" varies across studies

  • The percentage of negative nuclei needed for diagnosis is not standardized

• Technical variables:

  • Antibody concentration affects sensitivity

  • Different antigen retrieval methods may yield different results

  • Automated vs. manual staining can produce different staining intensities

• Biological variables:

  • Intratumoral heterogeneity may require sampling multiple regions

  • Some tumors show discordance between genetic SMARCB1 status and INI1 protein expression

  • Non-neoplastic cells within the tumor serve as internal positive controls

To minimize these pitfalls, it is recommended to run appropriate positive and negative controls with each staining batch and to correlate IHC results with molecular findings when available.

How is INI1 antibody testing being used in clinical trials and targeted therapy development?

INI1/SMARCB1 status is increasingly being incorporated into clinical trial eligibility criteria and targeted therapy development:

• EZH2 inhibitors: Loss of INI1 leads to epigenetic dysregulation, with EZH2 (enhancer of zeste homolog 2) overexpression. Clinical trials are evaluating EZH2 inhibitors specifically in INI1-deficient tumors.

• CDK4/6 inhibitors: INI1 loss leads to dysregulation of the cell cycle, potentially creating vulnerability to CDK4/6 inhibition.

• Immunotherapy approaches: The observation that some INI1-deficient tumors show increased PD-L1 expression and CD8+ T-cell infiltration has led to trials of immune checkpoint inhibitors in these patients .

• Combination approaches: Trials combining epigenetic modifiers with immunotherapy based on INI1 status are in development.

The methodological approach involves screening patients with INI1 antibody testing, confirming loss through molecular techniques, and then stratifying patients based on both INI1 status and other biomarkers.

What is the role of INI1 antibody in understanding the function of the SWI/SNF complex in gene regulation?

INI1 antibody has been instrumental in elucidating the role of the SWI/SNF complex in gene regulation:

• Chromatin immunoprecipitation (ChIP): INI1 antibodies enable mapping of INI1 binding sites across the genome and identification of target genes

• Protein complex analysis: Immunoprecipitation with INI1 antibodies followed by mass spectrometry has revealed novel interaction partners

• Dynamic assembly studies: INI1 antibodies help track the assembly and disassembly of SWI/SNF complexes during cellular processes

• Functional domains research: Studies like those on the Rpt1 domain's interaction with HIV-1 integrase use INI1 antibodies to validate structural models and binding interfaces

These applications extend beyond diagnostic pathology into fundamental research on chromatin remodeling and gene expression regulation.